Clinical Outcomes in Stage III Non-small Cell Lung Cancer Patients Treated with Durvalumab After Sequential Or Concurrent Platinum-based Chemoradiotherapy – Single Institute Experience

BACKGROUND: Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrankar, Martina, Stanic, Karmen, Jelercic, Stasa, Ciric, Eva, Vodusek, Ana Lina, But-Hadzic, Jasna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647791/
https://www.ncbi.nlm.nih.gov/pubmed/34821136
http://dx.doi.org/10.2478/raon-2021-0044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647791/
https://www.ncbi.nlm.nih.gov/pubmed/34821136
http://dx.doi.org/10.2478/raon-2021-0044

Ejemplares similares